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Abstract Breast cancer represents the second most fre-
quent etiology of brain metastasis (BM). It is estimated that
10–30 % of patients with breast cancer are diagnosed with
BM. Breast cancer BM are increasing due to the aging
population, detection of subclinical disease, and better
control of systemic disease. BM is a major cause of mor-
bidity and mortality affecting neurocognition, speech,
coordination, behavior, and quality of life. The therapy of
BM remains controversial regarding use and timing of
surgical resection, application of whole-brain radiotherapy,
stereotactic radiosurgery and systemic drugs in patients
with particular tumor subtypes. Despite numerous trials,
the range of interpretation of these has resulted in differing
treatment perspectives. This paper is a review of the state
of the art and a multidisciplinary guideline on strategies to
improve the therapeutic index in this situation.
Keywords Brain metastasis  Breast cancer  Subtypes 
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Introduction
Breast cancer represents the second most common etiology
of brain metastases (BM) and it is estimated that 10–30 %
of patients with breast cancer are diagnosed with BM [1].
The incidence of BM has been increasing, thought to be
due to the aging population, increased detection of sub-
clinical disease and better control of systemic disease.
Central nervous system (CNS) metastases are a major
cause of morbidity and mortality, affecting survival, neu-
rocognition, speech, coordination, behavior, and quality of
life. CNS metastases include brain, spinal cord, leptome-
ninges and eyes metastases. We believe that a correct
description of the incidence, prognosis, diagnosis and
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therapeutic approach of leptomeningeal metastasis requires
another whole article, therefore not be treated in this paper.
The BM process is complex, requiring invasion from the
primary tumor into surrounding tissue, extravasation into
the circulatory system and colonization and growth at a
distant site [1, 2]. Tumor cells may have or may acquire the
ability to preferentially colonize specific organ sites.
Moreover, the brain may represent a preferential site of
metastasis as many of the currently available therapies are
unable to cross the blood–brain barrier (BBB), even if this
barrier is disrupted by tumor invasion.
It is now recognized that breast cancer is composed of
several subtypes. A further increase in incidence of BM is
seen in patients with estrogen receptor (ER) negative as well
as HER2 positive breast cancers. With the advent of better
systemic therapies, BM is emerging as an increasing clinical
problem. In a retrospective series of metastatic breast car-
cinoma (MBC) patients who died, among the treated with
trastuzumab, 52 % seemed to succumb from CNS progres-
sion, in the face of stable or responsive non-CNS disease [3].
Relapse in the CNS represents a barrier to cure patients
with breast cancer. However, not all patients with BM have an
equally poor prognosis. Conventional treatment has been
whole-brain radiotherapy (WBRT), which can improve
symptoms but potentially results in neurocognitive deficits. In
addition, responses are often not durable. Historically, the
lack of durability was not a problem for most patients because
BM occurred late in the course of illness, and progression in
non-CNS sites was the dominant source of morbidity and
mortality. Thus, the development of novel approaches to the
treatment of CNS metastases has not previously been con-
sidered of high priority. Nevertheless, as systemic therapies
improve, there is concern that the incidence of BM will
increase, and that control of CNS disease will become a more
vital component of overall disease control and quality of life.
Topics covered in this review include:
• Incidence by tumor subtype.
• Mechanistic insights into the pathogenesis and recent
advances in defining the molecular underpinnings of
brain tropism.
• Diagnosis and prevention.
• Prognosis.
• Local treatments.
• Systemic anticancer treatments by tumor subtypes.
• Supportive care.
• Summary and multidisciplinary management guidelines
Incidence
The risk of developing BM varied according to stage at
initial diagnosis. Only 2.5 % of patients who initially
presented with localized disease ultimately developed CNS
disease, whereas 7.6 % of patients diagnosed with regional
disease, and 13.4 % of patients presenting with stage IV
disease were eventually found to have CNS involvement
[4–7]. BM may be the first manifestation of cancer
(5–10 %), may present synchronously with both systemic
and intracranial cancer (5–10 %) or, more commonly,
present metachronously and with known systemic cancer
([80 % of all patients). Single BM is seen in 20–30 % of
all patients and a similar percentage of patients have two or
three BM, so-called oligometastatic BM. A third or more of
patients have four or more BM, so-called polymetastatic
BM [5].
Several analyses support young age and a negative
ER as the main risk factors for the development of BM
in breast cancer patients. [7–9]. In a large study
involving 3,726 patients with early-stage breast cancer,
who were followed for 15 years, patients with HER2-
enriched breast cancer had the highest incidence of BM
(14.7 %) compared with 2.2, 4.7, 10.9 and 7.2 % for
patients diagnosed with luminal-A, luminal-B, tri-
ple-negative basal-like and triple-negative non basal
breast cancer, respectively [10]. Duchnowska et al.
studied the correlation between quantitative HER2
protein expression ratio by central laboratory fluores-
cence in situ hybridization (FISH) and risk for BM in
142 consecutive patients who have administered trast-
uzumab-based therapy for HER2 MBC. Their data
revealed a strong relationship between quantitative
HER2 protein expression level and the risk for brain
relapse [11].
Because most CNS metastases are diagnosed in
response to clinical symptoms rather than by routine
staging, the total incidence of BM may be underestimated.
Studies investigating MBC patients reported alarming
rates of BM among patients treated with trastuzumab-
based regimens, in the range of 14.8–48 % [3, 11–14].
The CEREBEL study, a trial designed to answer the
question of wheter lapatinib plus capecitabine (LC) were
superior to trastuzumab plus capecitabine (TC) in pre-
vention of MB in MBC patients after trastuzumab failure,
showed asymptomatic BM in 120 of 605 (19.8 %) patients
screened [15].
Early detection of asymptomatic BM has not yet
shown an improvement in overall survival (OS) but pro-
duces a three-fold decrease in cerebral deaths following
administration of WBRT [16]. Although this is a very
controversial issue, it is arguably that performing a cranial
MRI study in asymptomatic HER2-positive MBC patients
in progression to trastuzumab could be justified because
the information obtained by cranial MRI can change the
type of local or systemic treatment with the intention of
avoiding neurological complications.
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Mechanistic insights into the pathogenesis and recent
advances in defining the molecular underpinnings
of brain tropism
The wealth of information that can be gained by cross-
subtype comparison at the clinical and basic science levels
reflects the heterogeneity of breast carcinomas to BM
progression. The large numbers of genes differentially
expressed between the five molecular subtypes of breast
cancer confirm that the underline biology of the subtypes is
different [16]. The ability to predict metastatic potential
could be of great clinical importance, Some authors ana-
lyzed multiple primary tumors and metastasis pairs and
determined that[90 % of gene expression signatures were
found to be similarly expressed between matched pairs of
tumors and metastases. Therefore, primary tumors may be
a good predictor of metastatic propensity. BM occurred
most frequently in non-luminal samples, liver relapse was
associated with HER2-enriched tumors, and lung relapse
occurred often within the claudin-low and basal-like sub-
types [17, 18]. A gene expression analysis of laser-captured
epithelial cells carried out from resected human BM of
breast cancer compared with unlinked primary breast
tumors found several differentially expressed genes,
including phosphatase, glycosylphosphatidylinositol-
anchoring proteins, and those regulating extracellular
matrix and cell adhesion. Cyclooxygenase (COX) 2, epi-
dermal growth factor receptor (EGFR) ligand HBEGF and
ST6GALNACS, a sialyltransferase, have been identified
that specifically mediates BM development [19, 20]. An
accurate classification of BM proteins by mapping organ-
specific BM gene expression signatures found 37 proteins
differentially expressed between primary breast tumors
with BM and primary breast tumors without BM. Among
them GRP94, FN14, and inhibin were the best combination
to discriminate between brain and non-BM (ROC AUC
0.85, 95 % CI 0.73–0.96 for the combination of the three
proteins) [21]. These markers substantially improve the
prediction of BM compared with HER2 alone (ROC AUC
0.76, 95 % CI 0.60–0.93). Finding a genetic signature that
shows an increased risk of BM would be useful for more
intense monitoring plan to early diagnoses or in the design
of BM preventive therapies.
The brain is a site which places different demands on the
invading tumor cells, which are compelled to establish glial
interactions to colonize it [22]. Moreover, a essential step
of metastasis formation is at the vascular branch points,
where the persistent close contact between metastatic cells
to microvessels induces a perivascular growth by vessel
cooption [23]. Within this framework, activated astrocytes
surround and infiltrate BM. Being the most active host cell
population, they immediately localize individual invading
metastatic cells and continually associates with growing
metastatic lesions [24]. Functional characterization of
genes/proteins differentially expressed in the BM need to
be investigated with a focus on determining which gene or
set of genes may be critical for establishing growth in the
brain. This will provide the identification of novel molec-
ular targets for prevention and treatment.
Diagnosis and prevention
While a cranial CT-scan is able to detect the majority of
CNS metastases, sensitivity and specificity is markedly
greater in gadolinium enhanced magnetic resonance
imaging (MRI) [25].
A precise determination of the extent of disease is
clearly essential for choice the appropriate therapeutic
approach. A single BM must be differentiated from mul-
tiples BM. Moreover, a solitary lesion is defined by the
absence of any extracranial tumor and single BM means
that can there are other metastases or primary tumor out-
side CNS.
In such cases, primary CNS tumors and CNS infection
must be differentiated from a solitary metastasis. Ruling
out these diagnoses often requires a biopsy. In a random-
ized study, the initial diagnosis of a single BM could not be
maintained in 11 % of the subjects [26]. BM are initiated
mainly at the border between the gray and white matter.
The majority are distributed in the cerebral hemispheres
(80 %), followed by the cerebellum (15 %) and brain stem
(5 %).
BM may be either symptomatic or asymptomatic. Early
diagnosis of CNS involvement may be crucial for the
patient because neurological symptoms, once developed, do
not often resolve completely, even in patients responding to
treatment. Therefore, quality of life could be maintained for
longer in patients who are diagnosed timely [27].
Patients are diagnosed when BM, containing millions of
tumor cells, are sufficiently large to be observed with
imaging. The elimination of occult micrometastases serves
as the rationale behind giving WBRT. However, prophy-
lactic WBRT is not free of long-term side effects. Also
whether all micrometastasis progressively grow, or alter-
natively, some enter periods of tumor dormancy, remains a
relevant issue. Certain cancers, such as those of the breast,
recur years after the primary diagnosis in some patients,
suggesting that the tumor cells may lie dormant in a distant
location for long periods of time [28]. Prophylactic WBRT
therefore is not indicated outside clinical trials.
Given that a high proportion of HER2-overexpressing
breast cancer patients will develop symptomatic BM, it is
critical to discuss whether or not those patients should be
followed with regular MRI scans for detected asymptom-
atic BM. In our opinion, if a therapeutic approach depends
438 Clin Transl Oncol (2014) 16:436–446
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on a precise determination of the extent of disease and
asymptomatic BM is present in 20–30 % of patients [15],
MRI scan could be justified [29, 30]. And for this reason,
we believe that in case of relapse HER2postive breast
cancer, MRI is indicated as extension study.
The CEREBEL study was designed to demonstrate that
the combination of LC was able to reduce the incidence of
BM compared to TC in patients with HER2-positive MBC
[31]. After pre-specified interim analysis including 475
patients, the incidence of BM as first relapse was 3 % for
LC vs 4 % for TC (OR 95 % CI 0.75 (0.25, 2.20). The
median progression free survival (PFS) was 6.6 and
8.0 months in LC and TC arms (HR 1.3; 95 % CI 1.0, 1.7)
and median OS was 22.4 and 27.3 months (HR 1.58; 95 %
CI 1.07, 2.32). For these results the study was closed early.
Prognosis
Historically, the OS of patients with breast cancer meta-
static to brain has been poor, ranging from 3 to 6 months
[32]. Less than 20 % of patients survived [1 year. The
appropriate management of patients with BM from breast
cancer requires an assessment of independent prognostic
factors in order to maximize survival and neurologic
function whilst avoiding unnecessary treatments. These
important variables include: performance status, commonly
Karnofsky performance status score (KPS), number of BM,
tumor histology, pathological grading, hormone receptor
status, systemic tumor activity (controlled vs uncontrolled)
and age less than 65 years. Of these, the KPS score has
consistently been shown to be the major determinant of
survival in most studies.
On the other hand survival in MBC patients with BM
greatly depends on adequate therapy of both BM and
extracranial disease. In untreated patients, survival may be
as short as 1–2 months. After WBRT, survival may
increase up to 3–6 months. Patients with solitary BM have
a more favorable course of disease, and a median survival
time of 14–25 months may be reached. Patients who
received systemic hormone therapy or chemotherapy after
local therapy of BM had longer survival duration
(7.8 months) than those who did not (3.6 months) [33].
The Radiation Therapy Oncology Group (RTOG)
established 3 prognostic categories using recursive parti-
tioning analysis (RPA) of their database [34] (see Table 1).
Although the distinction of single vs multiple BM did not
retain significance in the original RPA model, it may hold
additional prognostic value within classes 1 and 2. OS for
patients with a single BM is 13.5 months for RPA class 1
and 6 months for RPA class 2 [35].
For this reason Sperduto et al. [36], using the updated
RTOG data base, recently suggested a new prognostic
scoring system, named Graded Prognostic Assessment
(GPA) index. The GPA partitioned patients with BM into
four categories ranging in median OS from 2.6 to
11 months (see Table 2). This score has been validated in
subsequent studies [37]. Most recently, the GPA has been
applied to patients with specific tumor subtypes to develop
a diagnosis-specific GPA, which is superior for predicting
prognosis [38].
Several groups have published retrospective studies
describing improved survival from time of BM diagnosis in
patients with HER2-positive, compared with HER2-nega-
tive breast cancers. Among patients treated at the Massa-
chusetts General Hospital from 1998 to 2003, the median
survival was also significantly longer in HER2-positive
patients (22.4 vs 9.4 months; p = 0.0002) [39]. In the
experience of Niwinska et al. [33] OS was different
depending on biological subtypes. Triple negative breast
cancer patients had the worst (4 months) and luminal had
the best (14 months). In the study of MD Anderson Cancer
Center, patients with triple negative tumors showed poor
survival [40].
Local treatment
Three local treatments are basically used for BM, namely
surgical resection (SR) stereotactic radiotherapy (SRT) and
whole brain WBRT. In spite of the long time that all these
techniques have been widely available, several questions
concerning optimal management remain unanswered in the
literature.
The efficacy of SR of BM was demonstrated by Patchell
et al. [41]. They randomly assigned 48 patients with a single
BM, only three of whom had breast cancer, to either SR
followed by WBRT or needle biopsy and WBRT. Brain
recurrence (BR) was less frequent in the surgical group than
in the radiation alone group (20 vs 52 %; p \ 0.02). The








MS in m [31]
1 KPS C70 and age \65 and
controlled primary tumor
and no extra cranial
metastases
7.1 15
2 KPS C70 and age C65 or
uncontrolled primary tumor
or extra cranial metastases
4.2 11
3 KPS \70 2.3 3
MS median survival, m months, KPS Karnofsky performance status,
BM brain metastases, WBRT whole-brain radiotherapy
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median OS was significantly longer in the surgical group
than in the radiation group (40 vs 15 weeks; p \ 0.01), and
patients treated with surgery remained functionally inde-
pendent longer (median of 38 vs 8 weeks; p \ 0.005).
Several retrospective studies have compared
SR ? WBRT with SRT ? WBRT. All of them reported no
significant differences on OS or longer time to BR except
for one, that showed an improvement for SR, although
probably there may have been a selection bias, since SRT
patients were poor candidates for surgery [42]. In addition,
patients may undergo SR of a lesion before WBRT, or
WBRT may be used in combination with SRT [43].
In the last years, however, some changes of the state of
the art in the radiation treatment for BM have been iden-
tified. Results of randomized trials showed that BR was
high if adjuvant WBRT was not delivered after local
treatment [27]. However, controversy has appeared con-
cerning the use of WBRT after SR or SRT of brain olig-
ometastasis. Several randomized trials have been unable to
demonstrate an OS improvement [43–45]. The recent
EORTC trial has shown that BR was significantly more
frequent in the observational arm (78 %) than in the
WBRT arm (48 %) [45]. Although, neurocognitive out-
comes [46] and quality of life [47] were worse in the early
WBRT group. Therefore, some authors suggest that WBRT
after SR or SRS could be avoided in some cases, especially
in patients with subtypes of MBC who live longer than the
the more aggressive triple negative subtypes [48].
The majority of patients with BM are given conven-
tional WBRT, a total dose of 30 Gy in 10 fractions and
daily fractions of 3–4 Gy [49]. Nevertheless, acute
encephalopathy has been reduced using lower fractions
(B3 Gy).
Re-irradiation has also been explored by several authors.
Specifically, RPA class 1 and 2 patients should be con-
sidered for repeat radiotherapy [50].
In conclusion, management of a single BM should be
started with local treatment unless a really low KPS is
present. In some of these patients WBRT may be delayed.
If more than four BM are found, WBRT is the standard
treatment (See Fig. 1).
Systemic anticancer treatment by tumor subtypes
Treatment of BM from luminal breast cancer (LBC)
Brain metastasis in this subtype of breast cancer appears in
lower rates and latest over the course of the disease com-
pared to HER2 positive and triple negative subtypes [51].
No global consensus exists regarding the ideal treatment
strategy for BM in LBC but systemic treatment appears to
enhance OS. In a retrospective study of over 135 patients
with BM from LBC, 88.8 % of them received local therapy
(WBRT, RS or SRT), 56.7 % chemotherapy (mostly with
taxanes) and 30.6 % hormonal therapy (mostly with aro-
matase inhibitors). Systemic treatment (chemother-
apy ± hormonal therapy ± target therapy) prolonged
median OS (14.3 vs 7.1 months, p = 0.03) [52]. These data
have been recently confirmed in a prospective study
including 420 patients: OS with systemic treatment after
WBRT increased 9 months in LBC [33].
Evaluation of ER is an important predictive factor for
BM response to therapy. BM from breast cancer frequently
show changes in hormonal receptors compared to matched
primary tumors. Loss of hormonal receptor positivity in
BM is more frequent than its gain [53]. Most randomized
trials in MBC with endocrine therapy exclude any degree
of brain or leptomeningeal spread but response of BM to
endocrine therapy has been reported in a few patients.
Tamoxifen and megestrol acetate are active against BM
[54, 55]. Notably tamoxifen and its metabolites have been
Table 2 Graded Prognostic
Assessment (GPA) index:
(A) GPA score B, (B) Median
survival for GPA index brain
metastases from breast cancer
patients according to GPA index
CNS central nervous system,
KPS Karnofsky performance




Age [60 50–59 \50








GPA 0–1 1.5–2 2.5–3 3.5–4
OS in months
All tumors [36]
3.1 5.4 9.6 16.7
OS in months
Breast cancer [38]
3.4 7.7 15.1 25.3
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reported to achieve high concentrations in the CNS; up to
46-fold higher in BM and brain tissue than in serum [56].
Although there are no data regarding concentration of
aromatase inhibitors in brain tissue, responses with le-
trozole and anastrozole have been reported [57, 58].
In conclusion: BM in LBC must be treated with local
therapy plus systemic treatment. This systemic treatment
will depend on ER in BM, KPS, extracranial disease,
previous systemic treatments and patient’s preference.
Treatment of BM from triple negative breast cancer
Actually systemic treatment in triple negative tumors is
limited to chemotherapy. So far, there is not an especially
approved drug against BM, neither there is a specific
designed trial including patients with BM from triple
negative breast cancer. We believe it is essential to
develop this type of studies with chemotherapy alone or in
combination with new target therapies as monoclonal
antibodies or tyrosine kinasa inhibitors against EGFR,
MET, VGEF, PI3K, or others. Response rate (RR) of BM
to chemotherapy, in patients who have not been heavily
pretreated, have generally been similar to those of primary
tumors. It was thought that the integrity of the BBB
limited delivery of large and hydrophilic drugs to the site
of BM. In addition, P-glycoprotein is highly expressed by
the brain capillary endothelium and actively mediates the
efflux of anthracyclines, taxanes, and vinca alkaloids.
However, if a BM presents contrast enhancement on CT
and MRI, its means that the BBB is partially disrupted and
hydrophilic drugs could pass [59]. The degree to which a
given agent is believed to penetrate the BBB is usually
based on pharmacokinetics animal and/or human studies
comparing plasma with cerebrospinal fluid drug concen-
trations after i.v. or oral administration. This method may
underestimate the concentration of drug delivered to the
tumor [60].
Clinical data supporting effectiveness of chemotherapy
for BM are limited primarily to several phase II studies,
often carried out in heavily pretreated patient populations
and not specific for triple negative breast tumors (see
Table 3). It is important to recognize that adequate ran-
domized phase III trials with most of the currently avail-
able agents have not yet been conducted.
Objective RR in the range of 17–55 % have been
reported in patients with new BM treated with classical
chemotherapy combinations against MBC [61, 62]. These
regimens may be considered, either before or after WBRT,
in patients with newly BM who have not previously
received these chemotherapy combinations.
Fig. 1 Algorithm for the initial treatment of brain metastases.
Asterisk In all cases consider systemic treatment by tumor subtype.
KPS Karnofsky performance status, SRS stereotactic radiosurgery,
WBRT whole-brain radiotherapy, ±WBRT omission of up-front
WBRT is an alternative in patients who are closely observed for
progression after surgery or SRS and have an active systemic
treatment
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The combination of cisplatin and etoposide has shown
activity in two phase II studies [63]. Carboplatin may
achieve slightly higher CNS concentrations than cisplatin
and is an active agent in MBC. Although the combination
of carboplatin and lomustine showed a RR of 34 % [64].
Oberhoff et al. [65] reported a 37 % objective RR in 24
women treated with topotecan (1.5 mg/m2 daily for 5 days
every 3 weeks) for new BM, but Lorusso et al. [66]
reported a 0 % RR in another trial.
Temozolomide (TMZ) has a favorable BBB penetration,
but unfortunately has not shown activity in breast cancer
BM as a single agent [67] or in combination with vino-
relbine [68]. Modest RR have been reported for TMZ
combined with cisplatin or capecitabine in small phase II
studies, likely reflecting the activity of cisplatin or cape-
citabine rather than TMZ [69, 70].
There are several case reports suggesting that capecita-
bine has activity in new and recurrent BM from breast
cancer [71]. Larger studies are requested to establish its
potential role either as a single agent or in combination
with other treatment modalities.
Methotrexate is active in breast cancer and has good
BBB penetration at high doses. [72]; however, concern for
toxic leukoencephalopathy, particularly when administered
after WBRT, limits its use for many patients.
Gefitinib has not demonstrated efficacy in BM from
breast cancer in a phase II multicenter study [73].
Recent data suggest that bevacizumab, a monoclonal
antibody that binds human vascular endothelial growth
factor (VEGF) and inhibits angiogenesis, is safe and
effective for progressive BM from breast cancer [74].
Sunitinib and sorafenib, specific VEGF receptor tyrosine
kinase inhibitors, are probably able to penetrate the BBB.
Sorafenib has been shown to significantly reduce the
occurrence of BM [75] and there are trials currently under
development to analyze its efficacy as a treatment for BM.
In conclusion classical chemotherapy combinations as
CMF or FAC, Carboplatin or capecitabine should be con-
sidered, either before or after WBRT, in patients with
newly BM who have not previously received these che-
motherapy combinations.
Systemic treatment in HER2 positive brain metastases
Consensus guidelines on systemic treatment after BM in
HER2 positive breast cancer patients are lacking. Several
retrospective studies have demonstrated improved survival
with trastuzumab in HER2-positive MBC patients with
CNS metastasis [8, 76, 77]. Interestingly, lapatinib has
shown a promising activity against BM in clinical studies
[77–79]. Taken all these findings together, we can argue
that there is a role for systemic treatments in improving the
outcome of HER2 positive breast cancer with BM.
It has been reported that almost one-third of MBC
patients that receive trastuzumab eventually will develop
BM [8, 11]. Moreover, 50 % of these BM were diagnosed
in patients with controlled disease outside the CNS. One of
the possible explanations for the increased incidence of
BM in this population may be that trastuzumab is a large
molecule and it is not able to cross the BBB. Nevertheless,
there are some data that support that this agent can pene-
trate the BBB when it is not intact either by radiotherapy or
Table 3 Chemotherapeutic regimens with activity in brain metastases from breast cancer
Chemotherapy New or recurrent N RR (%) OS (m) Study (year) References
CTX ? 5FU ? PDN New 52 52 NR Rosner et al. (1986) [61]
CMF ? VCR ? PDN New 35 54 NR Rosner et al. (1986) [61]
AC New 6 17 NR Rosner et al. (1986) [61]
CMF or CAF New 22 55 6 Boogerd (1992) [62]
CDDP ? VP-16 New 56 38 8 Franciosi (1999) [63]
CBDCA ? CCNU Both 26 34 NR Colleoni (1997) [64]
Topotecan New 24 37 6.2 Oberhoff (2001) [65]
New 19 19 NR Lorusso (2006) [66]
TMZ Recurrent 19 0 NR Trudeau (2006) [67]
TMZ ? VNR Recurrent 21 11 NR Omuro (2006) [68]
TMZ ? CDDP Recurrent 15 40 5.5 Christodolou (2005) [69]
TMZ ? Cape. Both 24 18 NR Rivera (2006) [70]
Capecitabine Recurrent 20 45 NR Kurt (2007) [71]
HD MTX NR 9 33 6 Lassman (2006) [72]
CTX cyclophosphamide, 5FU 5-fluorouracil, PDN prednisone, CMF cyclophosphamide, methotrexate and 5-fluorouracil, CA cyclophosphamide
and doxorubicin, CAF cyclophosphamide, doxorubicin, and 5-fluorouracil, CDDP cisplatin, CBDCA carboplatin, CCNU lomustine, OS overall
survival, NR not reported, RR response rate, TMZ temozolomide, VNR vinorelbine, VP-16 etoposide, HD MTX high-dose methotrexate
442 Clin Transl Oncol (2014) 16:436–446
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by the cancer itself [80]. The efficacy data of continuing
trastuzumab-based regimens in the management of BM is
controversial. Some reports have demonstrated a signifi-
cant survival benefit with this drug after local treatment [8,
33, 76, 77] (see Table 4). In general, it is assumed that the
impact on OS is mainly due to control of systemic disease
rather than CNS.
Lapatinib is a small molecule with potential ability to
cross the BBB. In preclinical models, lapatinib showed
activity in inhibiting BM and reducing the number of large
HER2-transfected brain metastases [81]. In a phase III
clinical study, LC combination therapy was more effective
than capecitabine alone in reducing BM as the first site of
recurrence. BM relapses as first progression were 6 % in
capecitabine alone vs 2 % in the combination therapy;
p = 0.045 [82]. In line with these observations, Metro
et al. showed that patients treated with sequential combi-
nation of trastuzumab and LC had significantly longer
survival compared with patients treated with trastuzumab-
based treatments alone (27.9 vs 16.7 months; p = 0.01)
with a 31.8 % of responses. [83]. In another single center
retrospective study over 80 patients, Bartsch et al. [77]
reported that the use of trastuzumab and lapatinib, either
sequentially or concomitantly, with or without chemo-
therapy, was associated with a 72 % reduction in risk of
death compared with trastuzumab alone (p = 0.012), and
lapatinib therapy was shown to be an independent positive
predictor for better OS (HR 0.279; p = 0.012).
Two phase II trials have studied the role of lapatinib in
monotherapy for established BM in HER-2 positive breast
cancer previously treated with trastuzumab and WBRT.
Both reported a volumetric reduction of BM [78, 84]. Other
two phase II trials have evaluated LC combination, The
study LEAP [84] demonstrated a 21 % of responses with
LC, in 35 % of patients LC was administered before
WBRT. One randomized phase II study compare LC vs
lapatinib plus topotenan. The study was closed early
because of unacceptable toxicity in the topotecan arm but
reported a RR of 38 % in LC arm [85]. The LANDSCAPE
study used LC before WBRT in 48 patients and reported a
RR of 67 % in BM [79].
Trastuzumab or lapatinib administered concurrently
with WBRT also been studied and have reported a RR of
approximately 70 % [86, 87]
In conclusion, antiHER2 treatments, both trastuzumab
and lapatinib, after BM diagnosis confer a survival benefit.
Data of multiples studies suggest that lapatinib could be an
active drug for management of BM in HER2-positive
breast cancer, however, well designed prospective clinical
trials with uniform criteria are urgently needed in order to
define the specific role of these targeted agents in the
management of HER2 positive breast cancer BM.
Table 4 Efficacy of antiHER2 therapies after BM diagnoses
N Study Treatment RR (%) OS (m) TTP (m) p value
Park [76] 29 Retrosp. With TTZ NR 13.6 NR \0.001
39 Without 5.5
Brufsky [8] 258 Observational, prosp. With TTZ NR 17.5 NR \0.001
119 Without 3.8
Bartsch [77] 15 Retrosp. TTZ ? LPT NR Not reached NR \0.001
28 TTZ 13
9 CT 9
28 No systemic treat 3
Metro [83] 22 Retrosp. TTZ ? LPT ? CPT 31.8 27.9 5.1 0.01
23 TTZ NR 16.7
Sutherland [84] 34 Phase IV LPT 21 9 5.1
Lin [78] 240 Phase II LPT 6 6.4 NR
50 Post WBRT LPT ? CPT 20 NR 3.6
Bachelot [79] 44 Phase II LPT ? CPT 67 17
Pre WBRT
Lin [85] 22 Phase II Rando LPT ? CPT 38 NR NR
Post WBRT LPT ? TT 0
TTZ trastuzumab, BM brain metastases, CT chemotherapy, RR response rate, LPT lapatinib, CPT capecitabine, NR not reported, TT topotecan,
WBRT whole-brain radiotherapy
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Supportive care
Supportive or symptomatic therapy is mainly based on the
administration of steroids and anticonvulsants.
Vasogenic edema is commonly seen with BM, it con-
tributes to intracranial mass effect and often can be amelio-
rated with administration of oral steroids. Dexamethasone
(DXM) is most often used for several reasons, including the
fact that it is the most potent steroid, has the best CNS pen-
etration, the least mineralocorticoid side effects, the least
protein-bound steroid and has a long biologic half-life
(24–36 h) [88]. DXM dose–response data have never been
established and, therefore, an empiric dose of 4–16 mg/day
is used. Based on the biologic half-life, once or twice per day
is sufficient, although often DXM is administered four times
per day without a clear rationale. The lowest dose of DXM
that controls symptoms should be utilized. Asymptomatic
patients with BM do not require DXM and may therefore be
spared potential steroid-related toxicity. Prolonged use of
DXM (defined as longer than 3 weeks) is associated with the
emergence of steroid-related side effects (e.g., proximal
myopathy, weight gain, skin fragility) that may seriously
compromise patient quality of life. How rapidly can the
steroid be withdrawn is, again, an issue not evidence-based
but rather empiric and determined by patient symptoms.
The use of antiepileptic drugs (AEDs) in patients with
BMs should be reserved for patients with seizures and for
seizure prophylaxis immediately following surgical resec-
tion. Based on the recommendations of American Acad-
emy of Neurology guidelines and the European guidelines,
AED prophylaxis in patients with primary and metastatic
brain tumors should be abandoned [89, 90]. If AEDs are
indicated, emerging data recommend the use of nonen-
zyme-inducing AEDs to minimize drug interactions that
may confound the treatment of patients with cancer.
Summary and multidisciplinary management
guidelines
Based upon the bibliographic research and the expertise of
the authors the following conclusions are made:
1. Early diagnosis of CNS involvement may be crucial:
When a patient experiences a systemic relapse of a
HER2 positive tumor a cranial MRI could be
indicated in order to detect CNS involvement.
2. Patient’s performance status determination and neu-
rological symptoms evaluation are essential for an
appropriate management of BM.
3. Age is an important prognostic factor and should be
included in the decision-making algorithm.
4. A precise determination of disease extension outside
and inside the CNS is essential in therapy choice
decision-making, so cranial MRI and body CT-scan
are indicated for a correct management of BM.
5. If a solitary BM is suspected, a histology confirma-
tion by stereotactic biopsy or BM resection should be
recommended.
6. Local (SR, SRT and/o WBRT) and systemic treat-
ment decision should be taken by a multidisciplinary
team.
7. Unless KPS \70, 1–3 BM treatment should be
initiated with a local treatment (SR o SRT) and
WBRT may be delayed.
8. If more than three BM are found, WBRT should be
the standard treatment in HER2 negative tumours.
LC treatment is an alternative in HER2-positive
cases.
9. Knowledge of previous systemic treatments and
assessment of ER and HER2 expression or amplifi-
cation are essential for a precise determination of
systemic treatment options.
10. BM from luminal breast cancer must be treated with
systemic treatment after local therapy. This treatment
will depend on ER, KPS, extracranial disease,
previous systemic treatments and the patient’s
preference.
11. Both trastuzumab and lapatinib confer survival
benefit in BM from HER2- positive cancer. Lapatinib
plus capecitabine have demonstrated volumetric
reduction in phase II trials and could delay WBRT.
12. The best treatment approach should include patient’s
participation in a clinical trial.
Conflict of interest None.
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